Monthly
US$200
Billed every month
甲泼尼龙片
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders10View records ↓
Under-review filings3View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers11View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 10 holders; 2 in the quality-and-efficacy consistency-evaluation category, and 7 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 上海理想制药有限公司 | 江苏鹏鹞药业有限公司 | 国药准字H20264358 | 2026/05/19 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉九珑人福药业有限责任公司 | 武汉九珑人福药业有限责任公司 | 国药准字H20254178 | 2025/05/13 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团容生制药有限公司 | 国药集团容生制药有限公司 | 国药准字H20253585 | 2025/03/11 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 濮阳市汇元药业有限公司 | 濮阳市汇元药业有限公司 | 国药准字H20249247 | 2024/11/05 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江仙琚制药股份有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20247189 | 2024/08/15 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辰欣药业股份有限公司 | 辰欣药业股份有限公司 | 国药准字H20243986 | 2024/06/11 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 瀚晖制药有限公司 | 瀚晖制药有限公司 | 国药准字H20237161 | 2023/11/23 | 4mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江仙琚制药股份有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20213809 | 2021/10/26 | 16mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华鲁抗医药有限公司 | 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20213671 | 2021/08/25 | 4mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 天津天药药业股份有限公司 | 国药准字H20020224 | 2020/03/03 | 4mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| Pfizer Italia s.r.l | Pfizer Italia Srl | H20150245 | 1999/03/08 | 4mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 11 distinct approval numbers and 10 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010100698 | NHSA |
| 津药药业股份有限公司 | 国药准字H20020224 | 4mg | Category A (甲) | XH02ABJ061A001010100943 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010103182 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20253585 | 4mg | Category A (甲) | XH02ABJ061A001010103205 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010104127 | NHSA |
| 山东新华鲁抗医药有限公司 | 国药准字H20213671 | 4mg | Category A (甲) | XH02ABJ061A001010104131 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20213809 | 16mg | Category A (甲) | XH02ABJ061A001010104735 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20237161 | 4mg | Category A (甲) | XH02ABJ061A001010109853 | NHSA |
| Pfizer Italia s.r.l | 国药准字HJ20150245 | 4mg | Category A (甲) | XH02ABJ061A001010178720 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H20254178 | 4mg | Category A (甲) | XH02ABJ061A001010183319 | NHSA |
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010200698 | NHSA |
| 津药药业股份有限公司 | 国药准字H20020224 | 4mg | Category A (甲) | XH02ABJ061A001010200943 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010203182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010204127 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H20254178 | 4mg | Category A (甲) | XH02ABJ061A001010283319 | NHSA |
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010300698 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010303182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010304127 | NHSA |
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010400698 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010403182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010404127 | NHSA |
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010500698 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010503182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010504127 | NHSA |
| 上海理想制药有限公司 | 国药准字H20264358 | 4mg | Category A (甲) | XH02ABJ061A001010600698 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010603182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010604127 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H20249247 | 4mg | Category A (甲) | XH02ABJ061A001010703182 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010704127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010804127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001010904127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011004127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011104127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011204127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011304127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011404127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011504127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011604127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011704127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011804127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001011904127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001012004127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243986 | 4mg | Category A (甲) | XH02ABJ061A001012104127 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20247189 | 4mg | Category A (甲) | XH02ABJ061A001020104735 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 3 filings and 3 distinct first applicants.
Supplement 1 · Generic 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Pfizer Italia s.r.l;Pfizer Italia Srl | JYHB2600492 | Supplement | 2026/08/27 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司 | CYHS2601743 | Generic | 2026/07/21 | Not stated by source | CDE |
| 天津信谊津津药业有限公司 | CYHS2602621 | Generic | 2026/10/26 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 11 companies with A status and 7 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲泼尼龙 | 天津信谊津津药业有限公司 | Y20260000804 | I | Exact ingredient | 2026/10/19 | CDE |
| 甲泼尼龙 | 江西宇能制药股份有限公司 | Y20260000126 | I | Exact ingredient | 2026/02/14 | CDE |
| 琥珀酸甲泼尼龙 | 山东斯瑞药业有限公司 | Y20250001065 | I | Salt-normalized ingredient | 2025/12/26 | CDE |
| 琥珀酸甲泼尼龙 | 河南利华制药有限公司 | Y20230000732 | A | Salt-normalized ingredient | 2026/03/13 | CDE |
| 甲泼尼龙 | 山东斯瑞药业有限公司 | Y20240000084 | A | Exact ingredient | 2025/11/03 | CDE |
| 甲泼尼龙 | EUROAPI France | Y20230000994 | A | Exact ingredient | 2025/09/09 | CDE |
| 甲泼尼龙 | MAHARSHI PHARMA CHEM PRIVATE LIMITED | Y20230000498 | I | Exact ingredient | 2023/10/27 | CDE |
| 琥珀酸甲泼尼龙 | BIOFER S.P.A. | Y20220000842 | A | Salt-normalized ingredient | 2025/04/04 | CDE |
| 甲泼尼龙 | 河南利华制药有限公司 | Y20220000702 | A | Exact ingredient | 2026/07/09 | CDE |
| 甲泼尼龙 | 岳阳环宇药业有限公司 | Y20220000279 | I | Exact ingredient | 2022/05/09 | CDE |
| 琥珀酸甲泼尼龙 | 湖北葛店人福药业有限责任公司 | Y20210000507 | A | Salt-normalized ingredient | 2025/02/12 | CDE |
| 琥珀酸甲泼尼龙 | Pfizer Inc. | Y20210000237 | A | Salt-normalized ingredient | 2024/01/17 | CDE |
| 甲泼尼龙 | Pfizer Inc. | Y20210000200 | A | Exact ingredient | 2024/01/17 | CDE |
| 甲泼尼龙 | 津药药业股份有限公司 | Y20190009636 | A | Exact ingredient | 2024/09/30 | CDE |
| 琥珀酸甲泼尼龙 | Newchem S.p.A. | Y20190009288 | A | Salt-normalized ingredient | 2025/06/09 | CDE |
| 琥珀酸甲泼尼龙 | 浙江仙琚制药股份有限公司 | Y20190008953 | A | Salt-normalized ingredient | 2024/01/25 | CDE |
| 甲泼尼龙 | 浙江仙琚制药股份有限公司 | Y20190008952 | A | Exact ingredient | 2024/04/30 | CDE |
| 琥珀酸甲泼尼龙 | 辽宁海思科制药有限公司 | Y20190007224 | A | Salt-normalized ingredient | — | CDE |
| 琥珀酸甲泼尼龙 | 津药药业股份有限公司 | Y20190004740 | A | Salt-normalized ingredient | 2025/08/16 | CDE |
| 琥珀酸甲泼尼龙 | 重庆胜凯制药有限公司 | Y20190001305 | A | Salt-normalized ingredient | 2025/04/22 | CDE |
| 甲泼尼龙 | 天津天药药业股份有限公司 | Y20190000234 | I | Exact ingredient | 2019/04/01 | CDE |
| 琥珀酸甲泼尼龙 | 江苏威奇达药业有限公司 | Y20180000958 | I | Salt-normalized ingredient | 2018/08/01 | CDE |
| 甲泼尼龙 | 湖北葛店人福药业有限责任公司 | Y20170001217 | A | Exact ingredient | 2026/06/12 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/26Accepted
-
2026/08/27Accepted
Pfizer Italia s.r.l;Pfizer Italia Srl
JYHB2600492
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy